Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

NCT04001413 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Sponsor withdrew funding

Conditions

HPV Positive Oropharyngeal Squamous Cell Carcinoma
Oropharynx Cancer
HPV-Related Carcinoma

Interventions

DRUG: MEDI0457
DRUG: Durvalumab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]